Durvalumab
Monoclonal antibody targets CD274 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 17 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (15) | US (FDA) | IMFINZI | — | 2018-02-16 – 2026-05-28 | fda.gov ↗ |
| Approved | EU (EMA) | Imfinzi | — | 2018-09-21 | europa.eu ↗ |
| Approved | US (FDA) | IMFINZI | — | 2017-05-01 | fda.gov ↗ |
Trials 729 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 011 trials | ||||||
| Phase 0 | NCT06824363 | May 2026 → Jan 2027 expected | esophageal adenocarcinoma, gastric adenocarcinoma | University of California, Irvine | Recruiting | No outcome recorded |
| Phase 0 | NCT04223648 | Aug 2020 → Feb 2022 | melanoma | Yale University | Withdrawn | No outcome recorded |
| Phase 0 | NCT04088032 | Oct 2019 → Dec 2020 | female breast carcinoma, hormone receptor-positive breast cancer | Alison Stopeck | Withdrawn | No outcome recorded |
| Phase 0 | NCT03818776 | Aug 2019 → Jan 2022 | non-small cell lung carcinoma | Case Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 0 | NCT03618654 | Nov 2018 → Nov 2021 | oral cavity squamous cell carcinoma, oropharynx squamous cell carcinoma | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 0 | NCT03235869 | Mar 2018 → Mar 2023 | primary cutaneous T-cell lymphoma | University of Michigan Rogel Cancer Center | Withdrawn | No outcome recorded |
| Phase 0 | NCT03215095 | Jul 2017 → Feb 2023 overdue | thyroid cancer | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03132467 | Jun 2017 → Jan 2019 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, progesterone-receptor positive breast cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT02812420 | Mar 2017 → Dec 2027 expected | hydronephrosis, infiltrating bladder urothelial carcinoma sarcomatoid variant, kidney pelvis sarcomatoid transitional cell carcinoma, micropapillary variant infiltrating bladder urothelial carcinoma +3 | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT02827838 | Jan 2017 → Apr 2022 | human papilloma virus infection, oral cavity squamous cell carcinoma, oropharynx squamous cell carcinoma | Wake Forest University Health Sciences | Terminated | No outcome recorded |
| Phase 0 | NCT02802098 | May 2016 → Jun 2019 | breast cancer | Spanish National Cancer Research Centre | Completed | No outcome recorded |
| Phase 1126 trials | ||||||
| Phase 1 | NCT05403723 | Jun 2026 → Feb 2027 | small cell lung carcinoma | University of Maryland, Baltimore | Suspended | No outcome recorded |
| Phase 1 | NCT07531095 | Apr 2026 → May 2028 expected | small cell lung carcinoma | Amgen | Recruiting | No outcome recorded |
| Phase 1 | NCT07391670 | Mar 2026 → Aug 2027 expected | cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1 | NCT05733689 | Jun 2025 → Jun 2027 expected | gastroesophageal adenocarcinoma | University of California, Irvine | Recruiting | No outcome recorded |
| Phase 1 | NCT06963346 | Jun 2025 → Apr 2028 | urinary bladder cancer | H. Lee Moffitt Cancer Center and Research Institute | Suspended | No outcome recorded |
| Phase 1 | NCT06564623 | May 2025 → Mar 2029 expected | biliary tract cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 1 | NCT06898957 | May 2025 → Jun 2031 expected | small cell lung carcinoma | Amgen | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06710223 | Jan 2025 → Jun 2027 expected | hepatocellular carcinoma | University of California, San Diego | Recruiting | No outcome recorded |
| Phase 1 | NCT06551142 | Sep 2024 → Oct 2028 expected | neoplasm | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 1 | NCT06058663 | Jun 2024 → Nov 2026 expected | intrahepatic cholangiocarcinoma | Mayo Clinic | Recruiting | No outcome recorded |
| Show all 126 trials opens the full record — a long page | ||||||
| Phase 1/297 trials | ||||||
| Phase 1/2 | NCT07269158 | Dec 2025 → Sep 2029 expected | biliary tract neoplasm | Yonsei University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06608940 | Nov 2025 → Jan 2027 | hepatocellular carcinoma | Case Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT07174583 | Oct 2025 → Jul 2029 expected | small cell lung carcinoma | IDEAYA Biosciences | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06911255 | Apr 2025 → Mar 2028 expected | hepatocellular carcinoma | Yoon Jun Kim | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06287775 | Apr 2025 → Jul 2029 expected | small cell lung carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06780137 | Feb 2025 → Apr 2029 expected | small cell lung carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06508216 | Jul 2024 → Dec 2025 overdue | breast cancer | Gustave Roussy, Cancer Campus, Grand Paris | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05932199 | Jul 2024 → May 2028 expected | mesothelioma | Baylor College of Medicine | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06255262 | Feb 2024 → Oct 2025 | biliary tract cancer | China Medical University, China | Unknown | No outcome recorded |
| Phase 1/2 | NCT06027086 | Feb 2024 → Sep 2028 expected | fibrolamellar hepatocellular carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05927142 | Jan 2024 → Apr 2026 overdue | pancreatic ductal adenocarcinoma | Joachim Aerts, MD PhD | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05451173 | Oct 2023 → Dec 2025 | non-small cell lung carcinoma | Alexander Chi | Unknown | No outcome recorded |
| Phase 1/2 | NCT05886439 | May 2023 → May 2027 expected | lung cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04989218 | Jan 2023 → Mar 2024 | cholangiocarcinoma | University of Alabama at Birmingham | Terminated | No outcome recorded |
| Phase 1/2 | NCT05327582 | Apr 2022 → Apr 2023 | biliary tract cancer, malignant pancreatic neoplasm | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT05325684 | Apr 2022 → Dec 2023 | — | The Affiliated Hospital of Qingdao University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04106115 | Mar 2022 → Mar 2027 expected | urinary bladder cancer | University College, London | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04781192 | Mar 2022 → Nov 2025 overdue | biliary tract cancer | University of Kansas Medical Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04711824 | Mar 2022 → Jul 2026 overdue | breast cancer, metastatic malignant neoplasm in the brain | Colette Shen | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06074029 | Dec 2021 → Dec 2023 | biliary tract cancer, immunotherapy induced hypophysitis | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT05187338 | Nov 2021 → Oct 2029 expected | breast cancer, cervical cancer, colorectal cancer, esophageal cancer +7 | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05120622 | Sep 2021 → May 2022 | bladder carcinoma in situ | University of British Columbia | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04748419 | Jul 2021 → Sep 2025 | non-small cell lung carcinoma | University of Nebraska | Terminated | No outcome recorded |
| Phase 1/2 | NCT04646837 | May 2021 → May 2024 | non-small cell lung carcinoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT04902040 | Apr 2021 → Feb 2025 | cutaneous melanoma, cutaneous neuroendocrine carcinoma, non-small cell lung carcinoma, renal cell adenocarcinoma +1 | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT04696848 | Feb 2021 → Mar 2023 | colorectal cancer | Tae Won Kim | Terminated | No outcome recorded |
| Phase 1/2 | NCT05267392 | Feb 2021 → Jul 2023 | non-small cell lung carcinoma | Instituto Portugues de Oncologia, Francisco Gentil, Porto | Unknown | No outcome recorded |
| Phase 1/2 | NCT04728230 | Jan 2021 → Dec 2027 expected | small cell lung carcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04538742 | Dec 2020 → Jan 2025 overdue | breast cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03245541 | Aug 2020 → Sep 2026 expected | pancreatic adenocarcinoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04124991 | Jun 2020 → Jul 2022 | hepatocellular carcinoma | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT04257448 | May 2020 → Jul 2024 | pancreatic ductal adenocarcinoma | GWT-TUD GmbH | Completed | No outcome recorded |
| Phase 1/2 | NCT04019288 | Dec 2019 → Oct 2024 | fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT03970616 | Sep 2019 → Apr 2023 | hepatocellular carcinoma | AVEO Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03802071 | Sep 2019 → Aug 2022 | sarcoma | Yonsei University | Completed | No outcome recorded |
| Phase 1/2 | NCT04068610 | Sep 2019 → Oct 2022 overdue | colorectal cancer | MedImmune LLC | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03871036 | May 2019 → Sep 2023 | urothelial carcinoma | The Netherlands Cancer Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT03829007 | Apr 2019 → Dec 2020 | head and neck cancer | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT03581487 | Apr 2019 → Oct 2025 | non-small cell lung carcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT03837899 | Mar 2019 → Feb 2023 overdue | childhood malignant neoplasm, hematopoietic and lymphoid cell neoplasm | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03694236 | Feb 2019 → May 2027 expected | — | Yonsei University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03742102 | Dec 2018 → Nov 2024 overdue | triple-negative breast carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03549715 | Dec 2018 → Jun 2024 | infiltrating bladder urothelial carcinoma | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | Unknown | No outcome recorded |
| Phase 1/2 | NCT03539822 | Oct 2018 → Jun 2028 expected | colorectal cancer, esophageal adenocarcinoma, gastric cancer, hepatocellular carcinoma | Anwaar Saeed | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03618134 | Oct 2018 → Jun 2023 | human papilloma virus infection, oropharynx squamous cell carcinoma | Jonsson Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT03721679 | Sep 2018 → Jan 2021 | — | Oncovir, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03376659 | Aug 2018 → Aug 2021 | colorectal adenocarcinoma, metastasis from malignant tumor of colon, pancreatic adenocarcinoma | Georgetown University | Terminated | No outcome recorded |
| Phase 1/2 | NCT03283605 | Jul 2018 → Jul 2024 | head and neck squamous cell carcinoma | University of Montreal Hospital Centre (CHUM) | Unknown | No outcome recorded |
| Phase 1/2 | NCT03594396 | Jun 2018 → Dec 2025 overdue | breast neoplasm | Seoul National University Hospital | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03611556 | Jun 2018 → Jul 2022 | pancreatic adenocarcinoma | MedImmune LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT03518606 | Jun 2018 → Apr 2022 | breast cancer, cervical cancer, head and neck cancer, prostate cancer | UNICANCER | Completed | No outcome recorded |
| Phase 1/2 | NCT03751761 | Jun 2018 → Aug 2023 | gastric cancer | Asan Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT03161223 | May 2018 → Feb 2023 overdue | T-cell non-Hodgkin lymphoma | University of Virginia | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03522584 | May 2018 → Dec 2021 | head and neck squamous cell carcinoma | University of Washington | Terminated | No outcome recorded |
| Phase 1/2 | NCT03051906 | Jan 2018 → Jan 2022 | head and neck neoplasm | Careggi University Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT03164772 | Dec 2017 → Oct 2021 | non-small cell lung carcinoma | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 1/2 | NCT03310619 | Dec 2017 → Feb 2023 | diffuse large B-cell lymphoma, follicular lymphoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT03308396 | Dec 2017 → Dec 2022 overdue | clear cell renal carcinoma | Ajjai Alva, MD | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03206073 | Dec 2017 → Sep 2020 | colorectal adenocarcinoma, refractory malignant neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT03317158 | Nov 2017 → Dec 2028 expected | urinary bladder cancer, urothelial carcinoma | Noah Hahn, M.D. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03249142 | Oct 2017 → Dec 2024 | ovarian cancer | ARCAGY/ GINECO GROUP | Completed | No outcome recorded |
| Phase 1/2 | NCT03148327 | Oct 2017 → Apr 2026 | non-small cell lung carcinoma | Jonsson Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT02963831 | Sep 2017 → Jun 2022 | appendix cancer, ovarian carcinoma | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 1/2 | NCT03202758 | Aug 2017 → Jan 2023 | colorectal cancer | Centre Georges Francois Leclerc | Completed | No outcome recorded |
| Phase 1/2 | NCT03323398 | Aug 2017 → Aug 2021 | ovarian cancer | ModernaTX, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03162224 | Jun 2017 → Mar 2021 | head and neck cancer, human papilloma virus infection | MedImmune LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT03116529 | Jun 2017 → Jun 2024 | soft tissue sarcoma | University of Maryland, Baltimore | Terminated | No outcome recorded |
| Phase 1/2 | NCT03212469 | Jun 2017 → Feb 2025 | esophageal cancer, head and neck squamous cell carcinoma, lung cancer | Gustave Roussy, Cancer Campus, Grand Paris | Completed | No outcome recorded |
| Phase 1/2 | NCT02898116 | May → Aug 2017 | non-small cell lung carcinoma | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 1/2 | NCT03356860 | Apr 2017 → Nov 2022 | luminal B breast carcinoma, triple-negative breast carcinoma | Grand Hôpital de Charleroi | Completed | No outcome recorded |
| Phase 1/2 | NCT03011814 | Mar 2017 → Apr 2030 expected | Sezary syndrome, folliculotropic mycosis fungoides, mature T-cell and NK-cell non-Hodgkin lymphoma, mycosis fungoides +1 | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02866747 | Jan 2017 → Nov 2024 | glioblastoma | Institut Claudius Regaud | Completed | No outcome recorded |
| Phase 1/2 | NCT02643303 | Dec 2016 → Feb 2022 | breast cancer, cutaneous neuroendocrine carcinoma, head and neck squamous cell carcinoma, kidney cancer +6 | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 1/2 | NCT02891161 | Nov 2016 → Aug 2019 | urothelial carcinoma | Monika Joshi, MD | Terminated | No outcome recorded |
| Phase 1/2 | NCT02962063 | Nov 2016 → Nov 2026 expected | esophageal adenocarcinoma, gastroesophageal junction adenocarcinoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02628132 | Nov 2016 → Dec 2019 | breast cancer | King Faisal Specialist Hospital & Research Center | Completed | No outcome recorded |
| Phase 1/2 | NCT02726997 | Jul 2016 → Dec 2027 expected | fallopian tube carcinoma, primary peritoneal carcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02735239 | Jun 2016 → Jun 2022 | esophageal cancer | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 1/2 | NCT02805660 | Jun 2016 → Dec 2019 | cancer of unknown primary site | Mirati Therapeutics Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT02733042 | May 2016 → Mar 2019 | B-cell chronic lymphocytic leukemia | Celgene Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT02685826 | Apr 2016 → Dec 2017 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT02583477 | Mar 2016 → Jul 2018 | pancreatic ductal adenocarcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1/2 | NCT02734004 | Mar 2016 → Sep 2021 overdue | breast disorder, gastric cancer, ovarian disorder, small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02671435 | Feb 2016 → Oct 2021 overdue | cancer | MedImmune LLC | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02431559 | Dec 2015 → Dec 2018 | ovarian cancer | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 1/2 | NCT02489448 | Nov 2015 → Jun 2021 | breast neoplasm | Yale University | Completed | No outcome recorded |
| Phase 1/2 | NCT02499328 | Aug 2015 → Feb 2020 | head and neck squamous cell carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1/2 | NCT02484404 | Jun 2015 → Oct 2027 expected | breast cancer, colorectal cancer | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02401048 | May 2015 → Nov 2017 | diffuse large B-cell lymphoma, follicular lymphoma | Pharmacyclics LLC. | Completed | No outcome recorded |
| Phase 1/2 | NCT02291055 | Apr 2015 → Jul 2019 | cervical cancer, head and neck cancer | Advaxis, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT02340975 | Mar 2015 → Apr 2019 | adenocarcinoma | MedImmune LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT02311361 | Mar 2015 → Oct 2019 | malignant pancreatic neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT02403271 | Mar 2015 → Aug 2017 | breast cancer, malignant pancreatic neoplasm, non-small cell lung carcinoma | Pharmacyclics LLC. | Completed | No outcome recorded |
| Phase 1/2 | NCT02318277 | Jan 2015 → Aug 2019 | head and neck cancer, lung cancer, urothelial carcinoma | Incyte Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT02205333 | Aug 2014 → Apr 2016 | aggressive B-cell non-Hodgkin lymphoma, cancer | MedImmune LLC | Terminated | No outcome recorded |
| Phase 1/2 | NCT02118337 | May 2014 → Mar 2020 | clear cell renal carcinoma, high grade malignant neoplasm | MedImmune LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT01693562 | Sep 2012 → Feb 2020 | cancer | MedImmune LLC | Completed | No outcome recorded |
| Phase 2402 trials | ||||||
| Phase 2 | NCT07639528 | Dec 2027 → Dec 2030 expected | intrahepatic cholangiocarcinoma | Northwestern University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07603856 | Dec 2026 → Jun 2030 expected | non-small cell lung carcinoma | University of Chicago | Recruiting | No outcome recorded |
| Phase 2 | NCT05253131 | Nov 2026 → Nov 2031 expected | malignant peripheral nerve sheath tumor, neurofibromatosis type 1 | University of Alabama at Birmingham | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07247786 | Sep 2026 → Dec 2031 expected | non-small cell lung carcinoma | Fundación GECP | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07146230 | Sep 2026 → Apr 2028 expected | non-small cell lung carcinoma | Montefiore Medical Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07459634 | Aug 2026 → Jan 2028 expected | small cell lung carcinoma | Jazz Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 2 | NCT07507968 | Jul 2026 → Feb 2030 expected | gastroesophageal adenocarcinoma | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06855225 | Jul 2026 → May 2027 expected | combined hepatocellular carcinoma and cholangiocarcinoma | Mehmet Akce | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07339059 | Jun 2026 → Feb 2029 expected | small cell lung carcinoma | Bindu R Potugari | Recruiting | No outcome recorded |
| Phase 2 | NCT07226063 | May 2026 → Feb 2028 expected | hepatocellular carcinoma | Amit Mahipal | Not yet recruiting | No outcome recorded |
| Show all 402 trials opens the full record — a long page | ||||||
| Phase 2/35 trials | ||||||
| Phase 2/3 | NCT06904170 | Nov 2025 → Sep 2029 expected | hepatocellular carcinoma | UNICANCER | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04628767 | Nov 2021 → Sep 2027 expected | renal pelvis/ureter urothelial carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05255653 | Nov 2021 → Jan 2030 expected | endometrial cancer | Leiden University Medical Center | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03258554 | Apr 2018 → Sep 2022 | hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, oral cavity squamous cell carcinoma, oropharynx squamous cell carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2/3 | NCT02766335 | Jul 2014 → Sep 2018 | non-small cell squamous lung carcinoma | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 376 trials | ||||||
| Phase 3 | NCT07637513 | Jan 2027 → Nov 2037 expected | small cell lung carcinoma | PrECOG, LLC. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07166406 | Feb 2026 → Mar 2029 expected | hepatocellular carcinoma | NRG Oncology | Recruiting | No outcome recorded |
| Phase 3 | NCT06992609 | Sep 2025 → Jun 2029 expected | small cell lung carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06732401 | Aug 2025 → Jun 2028 expected | non-small cell lung carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06841172 | Jul 2025 → Jul 2027 expected | hepatocellular carcinoma | Shandong Cancer Hospital and Institute | Recruiting | No outcome recorded |
| Phase 3 | NCT07027436 | Jul 2025 → Oct 2027 expected | hepatocellular carcinoma | Hamilton Health Sciences Corporation | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06960577 | May 2025 → Oct 2028 expected | urinary bladder cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06498635 | Apr 2025 → Jul 2039 expected | non-small cell lung carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 3 | NCT06284317 | Jan 2025 → Oct 2029 expected | non-small cell lung carcinoma | ETOP IBCSG Partners Foundation | Recruiting | No outcome recorded |
| Phase 3 | NCT06746116 | Dec 2024 → Nov 2028 expected | endometrial cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06719336 | Dec 2024 → Dec 2028 expected | small cell lung carcinoma | Anhui Shi, MD | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06282575 | Jul 2024 → Dec 2028 expected | biliary tract cancer | Jazz Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT06058377 | Nov 2023 → May 2032 expected | hormone receptor-positive breast cancer | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 3 | NCT06103864 | Nov 2023 → Jul 2027 expected | breast cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06112379 | Nov 2023 → Nov 2028 expected | breast cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06031597 | Sep 2023 → Dec 2025 | non-small cell lung carcinoma | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT05771480 | Aug 2023 → Oct 2025 overdue | biliary tract cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05943106 | Aug 2023 → Jun 2025 overdue | urinary bladder cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05924880 | Jul 2023 → Feb 2025 | biliary tract cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT05557838 | Feb 2023 → Sep 2026 expected | hepatocellular carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05687266 | Dec 2022 → Nov 2027 expected | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05629585 | Nov 2022 → Sep 2027 expected | breast cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05450692 | Sep 2022 → Oct 2025 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04637594 | May 2022 → Jun 2024 overdue | renal pelvis urothelial carcinoma | Alliance for Clinical Trials in Oncology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05298423 | May 2022 → Jun 2026 overdue | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05303532 | Apr 2022 → Dec 2026 expected | cancer | AstraZeneca | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT05301842 | Mar 2022 → Feb 2026 overdue | hepatocellular carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05211895 | Feb 2022 → Jul 2028 expected | non-small cell lung carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT05221840 | Feb 2022 → Sep 2026 expected | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04774380 | Nov 2021 → Jun 2023 | small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT05043090 | Oct 2021 → Dec 2025 overdue | papillary renal cell carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04585490 | Aug 2021 → Aug 2026 overdue | non-small cell lung carcinoma | Maximilian Diehn | Recruiting | No outcome recorded |
| Phase 3 | NCT04960709 | Aug 2021 → Mar 2026 overdue | urinary bladder carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04866017 | Jun 2021 → Oct 2023 | non-small cell lung carcinoma | BeiGene | Terminated | No outcome recorded |
| Phase 3 | NCT03673735 | Jun 2021 → Jul 2026 | head and neck squamous cell carcinoma | European Organisation for Research and Treatment of Cancer - EORTC | Withdrawn | No outcome recorded |
| Phase 3 | NCT04334759 | Feb 2021 → Jun 2025 | malignant pleural mesothelioma | PrECOG, LLC. | Completed | No outcome recorded |
| Phase 3 | NCT04712903 | Dec 2020 → Jun 2023 | small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT04449861 | Dec 2020 → Mar 2023 | small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT04642469 | Nov 2020 → May 2023 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT04592913 | Nov 2020 → Dec 2024 overdue | gastroesophageal cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04550260 | Oct 2020 → Jun 2027 expected | esophageal squamous cell carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04465968 | Sep 2020 → Aug 2027 expected | lung superior sulcus carcinoma, non-small cell lung carcinoma | National Cancer Center Hospital East | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04385368 | Jul 2020 → Aug 2023 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT04269200 | May 2020 → Jul 2024 overdue | endometrial cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04092283 | Apr 2020 → Dec 2028 expected | non-small cell lung carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03784014 | Oct 2019 → Dec 2023 | soft tissue sarcoma | French National Institute of Health and Medical Research | Completed | No outcome recorded |
| Phase 3 | NCT04026412 | Oct 2019 → Mar 2024 | non-small cell lung carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT03847428 | Apr 2019 → May 2026 overdue | hepatocellular carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03875235 | Apr 2019 → Aug 2021 overdue | biliary tract neoplasm | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03833154 | Mar 2019 → Oct 2028 expected | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03830866 | Feb 2019 → Jan 2022 | cervical carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT03737643 | Jan 2019 → Mar 2025 overdue | ovarian carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03800134 | Dec 2018 → Nov 2022 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03778957 | Nov 2018 → Sep 2023 overdue | hepatocellular carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03706690 | Nov 2018 → Jun 2024 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03732677 | Nov 2018 → Apr 2024 overdue | urinary bladder carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03682068 | Sep 2018 → Jun 2026 overdue | urothelial carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03703297 | Sep 2018 → Jan 2024 overdue | small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03288532 | Jul 2018 → Jul 2024 overdue | renal cell carcinoma | University College, London | Recruiting | No outcome recorded |
| Phase 3 | NCT03528694 | May 2018 → Apr 2025 overdue | non-invasive bladder urothelial carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03519971 | Mar 2018 → Sep 2023 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT03298451 | Oct 2017 → Aug 2021 overdue | hepatocellular carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03084471 | Jun 2017 → Mar 2020 | high grade malignant neoplasm | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT03164616 | Jun 2017 → Mar 2021 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03043872 | Mar 2017 → Jan 2020 overdue | small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03003962 | Jan 2017 → Oct 2022 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02542293 | Nov 2015 → Sep 2020 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02516241 | Nov 2015 → Jan 2020 overdue | urothelial carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02551159 | Oct 2015 → Jul 2020 | head and neck squamous cell carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02369874 | Sep 2015 → Sep 2018 | head and neck squamous cell carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02453282 | Jul 2015 → Oct 2018 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02454933 | Jul 2015 → Aug 2017 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT04116047 | Jul 2015 → Dec 2026 expected | oropharynx cancer | University of Birmingham | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02273375 | Feb 2015 → Jul 2025 overdue | non-small cell lung carcinoma | Canadian Cancer Trials Group | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02352948 | Jan 2015 → Feb 2018 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02125461 | May 2014 → Feb 2017 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT06908070 | Dec 2024 → Dec 2026 expected | non-small cell lung carcinoma | Idris Bahce | Recruiting | No outcome recorded |
| Phase 4 | NCT06031233 | Sep 2023 → Jul 2028 expected | — | Isala | Recruiting | No outcome recorded |
| Phase 4 | NCT04416633 | Nov 2021 → Oct 2023 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT04356222 | Jun 2020 → Jun 2023 | neoplastic meningitis | Hui Bu | Unknown | No outcome recorded |
| Phase 4 | NCT04078152 | Sep 2019 → Oct 2022 | cancer | AstraZeneca | Completed | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT06611345 | Oct 2024 → Oct 2026 expected | biliary tract cancer | Jiangsu Healthy Life Innovation Medical Technology Co., Ltd | Recruiting | No outcome recorded |
| — | NCT04517227 | Jul 2021 → Jun 2025 | hepatocellular carcinoma | Fudan University | Unknown | No outcome recorded |
| — | NCT04851132 | Mar 2021 → Mar 2023 | esophageal squamous cell carcinoma | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| — | NCT04443322 | Sep 2020 → Dec 2021 | hepatocellular carcinoma | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT04444193 | Aug 2020 → May 2021 | endometrial cancer | Shanghai First Maternity and Infant Hospital | Unknown | No outcome recorded |
| — | NCT02563925 | Sep 2015 → Jul 2021 | breast cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05345678 | — | hepatocellular carcinoma | AstraZeneca | Approved for marketing | No outcome recorded |
Also used as a comparator or background therapy in 87 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 115 trials | ||||||
| Phase 1 | NCT07700420 Background | Oct 2026 → Oct 2027 expected | esophageal cancer, gastroesophageal cancer | University of Texas Southwestern Medical Center | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07619313 Background | Jun 2026 → Jun 2027 expected | cholangiocarcinoma, pancreatic ductal adenocarcinoma | Jonsson Comprehensive Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07107750 Background | Mar 2026 → Jun 2030 expected | biliary tract cancer | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 1 | NCT05358691 Background | Nov 2024 → Dec 2027 | lung carcinoma | Rutgers, The State University of New Jersey | Withdrawn | No outcome recorded |
| Phase 1 | NCT06546969 Background | Oct 2024 → Dec 2027 expected | cholangiocarcinoma | University of Maryland, Baltimore | Recruiting | No outcome recorded |
| Phase 1 | NCT06302426 Background | Jul 2024 → Oct 2026 expected | neoplasm | Inimmune Corporation | Recruiting | No outcome recorded |
| Phase 1 | NCT06124118 Background | Apr 2024 → Nov 2026 expected | non-small cell lung carcinoma | University of Utah | Recruiting | No outcome recorded |
| Phase 1 | NCT05154994 Background | Jan 2022 → Aug 2026 overdue | infiltrating bladder urothelial carcinoma sarcomatoid variant | University of Utah | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05136846 Background | Dec 2021 → Dec 2026 expected | non-small cell lung carcinoma | Ohio State University Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT04900818 Background | Jun 2021 → Dec 2026 expected | biliary tract cancer, esophageal adenocarcinoma, gastric cancer, gastroesophageal cancer +2 | I-Mab Biopharma US Limited | Recruiting | No outcome recorded |
| Phase 1 | NCT05157542 Background | Jun 2021 → Jun 2023 | non-small cell lung carcinoma | Juan LI, MD | Unknown | No outcome recorded |
| Phase 1 | NCT04387084 Background | Aug 2020 → Aug 2026 overdue | skin cancer | University of Southern California | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03946800 Background | May 2019 → Aug 2023 | cancer | MedImmune LLC | Completed | No outcome recorded |
| Phase 1 | NCT02890368 Background | Sep 2016 → Mar 2020 | breast carcinoma, cutaneous neuroendocrine carcinoma, melanoma, mycosis fungoides +2 | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT02900157 Background | Aug 2016 → Jan 2020 | cancer | MedImmune LLC | Completed | No outcome recorded |
| Phase 1/210 trials | ||||||
| Phase 1/2 | NCT06694454 Background | Jul 2026 → Dec 2031 expected | non-small cell lung carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06939036 Background | Jul → Dec 2025 | cutaneous neuroendocrine carcinoma, small cell lung carcinoma | Ariceum Therapeutics GmbH | Terminated | No outcome recorded |
| Phase 1/2 | NCT06548412 Background | Jan 2025 → May 2027 expected | biliary tract cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06501625 Background | Dec 2024 → Jul 2026 overdue | IDH-mutant anaplastic astrocytoma | Servier | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06111326 Background | Oct 2023 → Aug 2024 | hepatocellular carcinoma | Biocity Biopharmaceutics Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04954599 Background | May 2023 → Feb 2027 expected | cancer of unknown primary site | Maastricht University Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03942328 Background | Sep 2019 → May 2030 expected | hepatocellular carcinoma, intrahepatic cholangiocarcinoma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03732274 Background | Feb 2019 → May 2024 | non-small cell lung carcinoma | MedPacto, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03616886 Background | Dec 2018 → Mar 2025 overdue | triple-negative breast carcinoma | Jules Bordet Institute | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03784066 Comparator | Aug 2018 → Mar 2025 overdue | oral cavity squamous cell carcinoma | Universitaire Ziekenhuizen KU Leuven | Active not recruiting | No outcome recorded |
| Phase 235 trials | ||||||
| Phase 2 | NCT07625930 Background | Jan 2027 → Apr 2029 expected | gastroesophageal adenocarcinoma | McGill University Health Centre/Research Institute of the McGill University Health Centre | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07332351 Background | Sep 2026 → Jan 2027 expected | infiltrating bladder urothelial carcinoma | University of Washington | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06274879 Background | May 2026 → Dec 2029 expected | bile duct cancer | Insel Gruppe AG, University Hospital Bern | Recruiting | No outcome recorded |
| Phase 2 | NCT07175441 Comparator | Apr 2026 → Apr 2027 expected | hepatocellular carcinoma | Riboscience, LLC. | Recruiting | No outcome recorded |
| Phase 2 | NCT07036380 Background | Dec 2025 → Nov 2028 expected | biliary tract cancer | Centre Hospitalier Universitaire de Besancon | Recruiting | No outcome recorded |
| Phase 2 | NCT06769126 Background | Nov 2025 → Dec 2028 expected | small cell lung carcinoma | SWOG Cancer Research Network | Recruiting | No outcome recorded |
| Phase 2 | NCT07172412 Background | Nov 2025 → Dec 2027 expected | small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06880523 Background | Oct 2025 → Jan 2028 expected | hepatocellular carcinoma | Canadian Cancer Trials Group | Recruiting | No outcome recorded |
| Phase 2 | NCT06858735 Background | Jun 2025 → Nov 2028 expected | intrahepatic cholangiocarcinoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06773910 Comparator | Mar 2025 → May 2032 expected | small cell lung carcinoma | SCRI Development Innovations, LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT06667908 Background | Dec 2024 → Dec 2028 expected | non-small cell lung carcinoma | Johnson & Johnson Enterprise Innovation Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06102057 Background | Jul 2024 → Jun 2026 overdue | non-small cell lung carcinoma | TheraOp | Recruiting | No outcome recorded |
| Phase 2 | NCT06502080 Background | Jul 2024 → Jun 2027 expected | biliary tract cancer | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05718297 Comparator | Jun → Sep 2024 | non-small cell lung carcinoma | ETOP IBCSG Partners Foundation | Withdrawn | No outcome recorded |
| Phase 2 | NCT06333678 Comparator | Mar 2024 → Jan 2026 | non-small cell lung carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT05161533 Background | Oct 2023 → Oct 2024 | small cell lung carcinoma | University of Washington | Withdrawn | No outcome recorded |
| Phase 2 | NCT05451043 Background | Jul 2023 → Oct 2026 expected | cholangiocarcinoma, hepatocellular carcinoma, malignant pancreatic neoplasm | AHS Cancer Control Alberta | Recruiting | No outcome recorded |
| Phase 2 | NCT05712356 Background | May 2023 → Apr 2026 | gallbladder carcinoma, intrahepatic cholangiocarcinoma | Lisata Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT05632809 Background | Jan 2023 → Dec 2027 expected | lung cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05198830 Background | Dec 2022 → Jun 2027 expected | lung adenocarcinoma, lung large cell carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT04105270 Background | Nov 2022 → Jan 2028 expected | lung adenocarcinoma | Masonic Cancer Center, University of Minnesota | Recruiting | No outcome recorded |
| Phase 2 | NCT04905316 Background | May 2021 → Jul 2026 | non-small cell lung carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT04660097 Background | May 2021 → Jun 2024 | small cell lung carcinoma | Henan Cancer Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04699838 Background | Apr 2021 → Jul 2026 overdue | small cell lung carcinoma | Muhammad Furqan | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03606967 Background | Apr 2021 → Dec 2026 expected | invasive breast carcinoma, triple-negative breast carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT04621370 Comparator | Dec 2020 → Jun 2025 | rectum adenocarcinoma | Cancer Research UK, Glasgow | Unknown | No outcome recorded |
| Phase 2 | NCT03847649 Comparator | Mar 2020 → Apr 2030 expected | cancer | Canadian Cancer Trials Group | Recruiting | No outcome recorded |
| Phase 2 | NCT03768570 Comparator | Oct 2019 → Oct 2026 expected | urinary bladder cancer | Canadian Cancer Trials Group | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03959293 Background | Jul 2019 → Mar 2022 overdue | gastric adenocarcinoma | Federation Francophone de Cancerologie Digestive | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03840902 Comparator | Apr 2019 → Feb 2023 | non-small cell lung carcinoma | EMD Serono Research & Development Institute, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT03994393 Comparator | Oct 2018 → Jun 2023 | lung cancer | University of Sydney | Unknown | No outcome recorded |
| Phase 2 | NCT03544723 Background | Oct 2018 → Jun 2022 | cancer, lymphoma | MultiVir, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT03057106 Comparator | Mar 2017 → Feb 2020 overdue | lung cancer | Canadian Cancer Trials Group | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02794883 Comparator | Nov 2016 → May 2018 | glioblastoma | Northwestern University | Completed | No outcome recorded |
| Phase 2 | NCT02452463 Background | Jun 2015 → Jun 2019 | non-small cell lung carcinoma, radiation pneumonitis | Roswell Park Cancer Institute | Terminated | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT06214572 Comparator | Mar 2024 → Jul 2029 expected | gallbladder cancer | Tata Memorial Centre | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06109272 Comparator | Jan 2024 → Sep 2030 expected | hepatocellular carcinoma | AbbVie | Recruiting | No outcome recorded |
| Phase 320 trials | ||||||
| Phase 3 | NCT07672223 Comparator | Jun 2026 → Sep 2029 expected | non-small cell lung carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07710885 Comparator | Jun 2026 → Apr 2030 expected | biliary tract cancer | Taiho Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07554339 Background | Jun 2026 → Dec 2032 expected | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT07361497 Comparator | Mar 2026 → Sep 2030 expected | non-small cell lung carcinoma | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 3 | NCT07229625 Comparator | Jan 2026 → Dec 2029 expected | biliary tract cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07195695 Comparator | Jan 2026 → Feb 2032 expected | non-small cell lung carcinoma | Boehringer Ingelheim | Recruiting | No outcome recorded |
| Phase 3 | NCT07221253 Comparator | Dec 2025 → Jul 2029 expected | biliary tract cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06840782 Background | Sep 2025 → Feb 2030 expected | non-small cell lung carcinoma | Gustave Roussy, Cancer Campus, Grand Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT07005128 Background | Aug 2025 → Jan 2029 expected | small cell lung carcinoma | Amgen | Recruiting | No outcome recorded |
| Phase 3 | NCT06890598 Background | Mar 2025 → May 2029 expected | non-small cell lung carcinoma | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT06591520 Comparator | Oct 2024 → Oct 2026 expected | biliary tract cancer | Akeso | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06467357 Comparator | Aug 2024 → Jun 2028 expected | biliary tract cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06211036 Background | Jun 2024 → Jul 2027 expected | small cell lung carcinoma | Amgen | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05624996 Background | Jul 2023 → Oct 2031 expected | non-small cell lung carcinoma | NRG Oncology | Recruiting | No outcome recorded |
| Phase 3 | NCT05170204 Comparator | Nov 2022 → Jun 2030 expected | non-small cell lung carcinoma | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05223647 Background | Jan 2022 → Sep 2025 | small cell lung carcinoma | Norwegian University of Science and Technology | Terminated | No outcome recorded |
| Phase 3 | NCT04597671 Background | Dec 2021 → Dec 2028 expected | non-small cell lung carcinoma | Association NVALT Studies | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04513925 Comparator | Aug 2020 → May 2025 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT04380636 Comparator | Jul 2020 → May 2027 expected | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01993810 Background | Jan 2014 → Nov 2028 expected | non-small cell lung carcinoma | Radiation Therapy Oncology Group | Active not recruiting | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT06484491 Background | Sep 2025 → Oct 2027 expected | non-small cell lung carcinoma | University Medical Center Groningen | Recruiting | No outcome recorded |
| — | NCT06702566 Background | Jul 2024 → Jul 2026 overdue | acute leukemia, cancer | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| — | NCT05834413 Background | May 2023 → Jun 2027 expected | lung cancer | Shanghai University of Traditional Chinese Medicine | Recruiting | No outcome recorded |
| — | NCT04985851 Comparator | Sep 2021 → Jun 2024 | small cell lung carcinoma | Shanghai Chest Hospital | Unknown | No outcome recorded |
| — | NCT02492867 Background | Jan 2016 → Nov 2021 | non-small cell lung carcinoma | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
Press releases naming this drug 44 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-01 | AstraZeneca | Imfinzi plus Imjudo combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolisation-eligible unresectable liver cancer in EMERALD-3 Phase III trial astrazeneca.com ↗ |
| 2026-05-28 | AstraZeneca | Imfinzi approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer. astrazeneca.com ↗ |
| 2026-05-14 | AstraZeneca | Perioperative Imfinzi plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial astrazeneca.com ↗ |
| 2026-04-02 | AstraZeneca | Imfinzi plus Imjudo combined with lenvatinib and TACE demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in embolisation-eligible unresectable liver cancer in EMERALD-3 Phase III trial astrazeneca.com ↗ |
| 2026-03-16 | AstraZeneca | Imfinzi approved in the EU as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers astrazeneca.com ↗ |
| 2026-02-02 | AstraZeneca | Imfinzi perioperative regimen recommended for approval in the EU by CHMP for patients with early gastric and gastroesophageal cancers astrazeneca.com ↗ |
| 2025-12-22 | AstraZeneca | Update on LATIFY Phase III trial of ceralasertib plus Imfinzi in previously treated advanced non-small cell lung cancer astrazeneca.com ↗ |
| 2025-11-25 | AstraZeneca | Imfinzi approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers astrazeneca.com ↗ |
| 2025-10-17 | AstraZeneca | Imfinzi regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial astrazeneca.com ↗ |
| 2025-10-17 | AstraZeneca | Imfinzi-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial astrazeneca.com ↗ |
| 2025-07-28 | AstraZeneca | Imfinzi granted Priority Review and Breakthrough Therapy Designation in the US for patients with resectable early-stage gastric and gastroesophageal junction cancers astrazeneca.com ↗ |
| 2025-07-04 | AstraZeneca | Imfinzi approved in the EU as first and only perioperative immunotherapy for muscle-invasive bladder cancer astrazeneca.com ↗ |
| 2025-06-01 | AstraZeneca | Imfinzi regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial astrazeneca.com ↗ |
| 2025-05-27 | AstraZeneca | Imfinzi recommended for approval in the EU by CHMP as first and only perioperative immunotherapy for muscle-invasive bladder cancer astrazeneca.com ↗ |
| 2025-05-09 | AstraZeneca | Imfinzi regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial astrazeneca.com ↗ |
| 2025-04-04 | AstraZeneca | Imfinzi-based perioperative regimen approved in the EU for resectable non-small cell lung cancer astrazeneca.com ↗ |
| 2025-03-31 | AstraZeneca | Imfinzi approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer astrazeneca.com ↗ |
| 2025-03-17 | AstraZeneca | Imfinzi approved in the EU as first and only immunotherapy for limited-stage small cell lung cancer astrazeneca.com ↗ |
| 2025-03-07 | AstraZeneca | Imfinzi-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers astrazeneca.com ↗ |
| 2025-03-03 | AstraZeneca | Imfinzi-based perioperative regimen recommended for approval in the EU by CHMP for resectable non-small cell lung cancer astrazeneca.com ↗ |
| 2025-02-14 | AstraZeneca | Imfinzi perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in post-hoc exploratory analysis of NIAGARA Phase III trial astrazeneca.com ↗ |
| 2025-02-03 | AstraZeneca | Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung cancer astrazeneca.com ↗ |
| 2024-12-06 | AstraZeneca | Imfinzi granted Priority Review in the US for patients with muscle-invasive bladder cancer astrazeneca.com ↗ |
| 2024-12-05 | AstraZeneca | Imfinzi approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer astrazeneca.com ↗ |
| 2024-09-16 | AstraZeneca | Imfinzi plus Imjudo demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial astrazeneca.com ↗ |
| 2024-09-15 | AstraZeneca | Imfinzi perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trial astrazeneca.com ↗ |
| 2024-08-16 | AstraZeneca | Imfinzi approved in the US for the treatment of resectable non-small cell lung cancer before and after surgery astrazeneca.com ↗ |
| 2024-08-15 | AstraZeneca | Imfinzi granted Priority Review and Breakthrough Therapy Designation for patients with limited-stage small cell lung cancer in the US astrazeneca.com ↗ |
| 2024-08-14 | AstraZeneca | Lynparza and Imfinzi combination approved in the EU for patients with mismatch repair proficient advanced or recurrent endometrial cancer astrazeneca.com ↗ |
| 2024-07-25 | AstraZeneca | FDA Advisory Committee reviewed Imfinzi for treatment of resectable non-small cell lung cancer based on AEGEAN Phase III trial results astrazeneca.com ↗ |
| 2024-07-01 | AstraZeneca | Lynparza and Imfinzi combination recommended for approval in the EU by CHMP for patients with mismatch repair proficient advanced or recurrent endometrial cancer astrazeneca.com ↗ |
| 2024-06-25 | AstraZeneca | Update on ADJUVANT BR.31 Phase III trial of Imfinzi in non-small cell lung cancer astrazeneca.com ↗ |
| 2024-06-25 | AstraZeneca | Imfinzi demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial astrazeneca.com ↗ |
| 2024-06-17 | AstraZeneca | Imfinzi plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer astrazeneca.com ↗ |
| 2024-06-02 | AstraZeneca | Imfinzi is first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo astrazeneca.com ↗ |
| 2024-04-16 | AstraZeneca | Imfinzi plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial astrazeneca.com ↗ |
| 2024-04-05 | AstraZeneca | Imfinzi significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial astrazeneca.com ↗ |
| 2024-03-18 | AstraZeneca | Lynparza and Imfinzi demonstrated strong clinical benefit and more than doubled median duration of response vs. chemotherapy in patients with mismatch repair proficient advanced or recurrent endometrial cancer astrazeneca.com ↗ |
| 2024-01-19 | AstraZeneca | Imfinzi plus transarterial chemoembolisation (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolisation astrazeneca.com ↗ |
| 2023-11-14 | AstraZeneca | Update on PACIFIC-2 Phase III trial of Imfinzi concurrently administered with platinum-based chemoradiotherapy in unresectable, Stage III non-small cell lung cancer astrazeneca.com ↗ |
| 2023-11-14 | AstraZeneca | Imfinzi plus chemotherapy approved in China as first immunotherapy regimen for patients with locally advanced or metastatic biliary tract cancer astrazeneca.com ↗ |
| 2023-11-09 | AstraZeneca | Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial astrazeneca.com ↗ |
| 2023-10-22 | AstraZeneca | Datopotamab deruxtecan plus Imfinzi demonstrated robust and durable tumour responses in 1st-line treatment of patients with metastatic triple-negative breast cancer in BEGONIA Phase Ib/II trial astrazeneca.com ↗ |
| 2023-10-21 | AstraZeneca | Imfinzi plus Lynparza reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer astrazeneca.com ↗ |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 827 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Durvalumab | “Standard of Care Drugs (at investigator's discretion) may include: pembrolizumab, nivolumab, cemiplimab, durvalumab, dostarlimab, avelumab, and atezolizumab, or other immune...” NCT07224971 ↗778“Successful organoids undergo drug sensitivity testing against a predefined panel of drugs (Gemcitabine + Cisplatin,Gemcitabine + Oxaliplatin,Durvalumab + Gemcitabine +...” NCT07351591 ↗ “The purpose of this study is to evaluate the safety, tolerability, and efficacy of MEDI4736 (durvalumab) alone and in combination with either tremelimumab or AZD9150 in adult...” NCT02549651 ↗ “The open-label, phase 1/2 ECHO-203 study evaluated the safety, tolerability, and efficacy of the IDO1 inhibitor epacadostat in combination with durvalumab, a human anti-PD-L1...” PMID 36309837 ↗ Oct 2022 “PD-L1 inhibitor Drug: Durvalumab OR pembrolizumab Durvalumab: During combination therapy: 1500 mg, Q3W, during combination therapy, on days 3-5 of each 3-week cycle (determined...” NCT07364305 ↗ “Durvalumab (1500 mg IV q4weeks) for 4 cycles in combination with tremelimumab. Then, durvalumab alone until confirmed disease progression, death, unacceptable toxicity,...” NCT03283605 ↗ “TTI-621 will be given in combination with one of the following programmed death-1 (PD-1) or programmed death-ligand-1 (PD-L1) inhibitors: nivolumab, pembrolizumab, durvalumab,...” NCT02890368 ↗ “combinations such as atezolizumab plus bevacizumab, tremelimumab plus durvalumab, or monotherapies such as lenvatinib, sorafenib, tislelizumab, durvalumab, or pembrolizumab, at...” NCT06841172 ↗ “This phase III study evaluated the efficacy of durvalumab (an anti-PD-L1 monoclonal antibody) or durvalumab plus tremelimumab (an anti-CTLA-4 monoclonal antibody) versus...” PMID 32294530 ↗ Apr 2020 “A Phase I/II Study of Paclitaxel Plus Carboplatin and Durvalumab (MEDI4736) With or Without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or...” NCT03616886 ↗ “Durvalumab is a human immunoglobulin G1 kappa monoclonal antibody which blocks the interaction between the programmed cell death ligand 1 (PD-L1) (a member of the B7 family)...” NCT05440864 ↗ “Enrolled patients received durvalumab/ Atezolizumab plus chemotherapy or target therapy treatment (durvalumab,1000mg，iv, d1, 21day as a cycle; Atezolizumab,1200mg iv, d1, 21day...” NCT05325684 ↗ “ICIs：Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab：administrated for patients with NSCLC requiring post-operative adjuvant therapy.” NCT05834413 ↗ “Patients received durvalumab (1500 mg every 4 weeks) plus tremelimumab (75 mg every 4 weeks) combination therapy for 4 cycles followed by durvalumab therapy (1500 mg every 4 weeks)” PMID 31318392 ↗ Oct 2019 “Durvalumab and Tremelimumab once in 4 weeks Durvalumab for 13 months Tremelimumab for initial 4 months Fulvestrant : At baseline, then week 2, week 4 and after that every 4 weeks” NCT03430466 ↗ “neoadjuvant Durvalumab, a monoclonal antibody targeting programmed cell death ligand 1, combined with Gemcitabine and Cisplatin or Carboplatin for high-risk UTUC patients.” PMID 37698632 ↗ Sep 2023 “Note: The specific PD-L1 inhibitor is selected by the researcher, such as adebelimab 1200mg iv, q3w; or atezolizumab 1200mg iv d1, q3w; or durvalumab 1500mg iv d1, q3w .” NCT06429696 ↗ “Dose level 1 Rituximab 375mg/m2 infusion once every 4 weeks for 8 cycles Acalabrutinib 100mg PO once every day Durvalumab 1500mg infusion once every 4 weeks” NCT04688151 ↗ “Specific agent (e.g., Pembrolizumab, Durvalumab, Toripalimab, or Tislelizumab) may be chosen based on local availability and patient access.” NCT07282262 ↗ “Durvalumab 1500 mg will be administered intravenously over 1 hour according to the usual q4 week schedule - with every other chemo cycle.” NCT07700420 ↗ “dual anti-PD-L1/CTLA-4 inhibition using durvalumab and tremelimumab can improve the clinical outcomes in advanced thyroid cancer.” PMID 41935063 ↗ Apr 2026 “Osimertinib (an EGFR TKI) plus durvalumab (programmed death-ligand 1 blockade) was evaluated in the TATTON study (NCT02143466).” PMID 35181499 ↗ Feb 2022 “We report a phase I, open-label study of the PD-L1 inhibitor durvalumab plus the CTLA-4 inhibitor tremelimumab (NCT02262741).” PMID 39043009 ↗ Jul 2024 “Neoadjuvant Anti-PD-L1 (Durvalumab/MEDI4736) Plus Anti-CTLA-4 (Tremelimumab) and Radiation for High Risk Soft-Tissue Sarcoma” NCT03116529 ↗ “nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+).” PMID 33643895 ↗ Feb 2021 “Durvalumab is a programmed cell death ligand 1 (PDL1) blocking antibody, that improves the immune response against cancer.” NCT04989218 ↗ “STRIDE regimen of Single Tremelimumab (high, priming 300-mg dose) Regular Interval Durvalumab (1500 mg every 4 weeks)” NCT06364007 ↗ “Durvalumab injection, 1500mg, IV, once every three weeks, completed on the first day until the disease progresses.” NCT04313660 ↗ “Other alternatives include nivolumab-ipilimumab-chemotherapy or durvalumab-tremelimumab-chemotherapy association.” NCT06840782 ↗ “The immunotherapy candidate of this study is durvalumab (MEDI4736) targeting PD-L1 (programmed death-ligand 1).” NCT05116254 ↗ “Pembrolizumab 200mg on day 1 of each 21-day cycle Durvalumab 1500 mg on day 1 of each 21-day cycle” NCT06567600 ↗ “Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC” NCT05668767 ↗ “Durvalumab 1500mg via IV infusion administered 6 and 3 weeks before radical cystectomy.” NCT05120622 ↗ “Patients will receive durvalumab (MEDI4736) and tremelimumab together every 4 weeks.” NCT03122496 ↗ “receive one infusion of Durvalumab (1500mg IV) / Tremelimumab 300mg IV) on Day 15.” NCT07027436 ↗ “standard of care consolidation therapy with durvalumab (fixed dose of 1500 mg q4w)” NCT06102057 ↗ “Immune Checkpoint Inhibitors including Durvalumab, Pembrolizumab and Toripalimab” NCT06074029 ↗ “Durvalumab treatment is to begin six weeks following patient ESD/EMR surgery.” NCT05667298 ↗ “PD-L1 inhibitor includes durvalumab,Atezolizumab,Adebrelimab,Envafolimab.” NCT06702566 ↗ “evaluated adjuvant durvalumab in completely resected early-stage NSCLC.” PMID 41529222 ↗ Jan 2026 “Radiation Therapy in combination with Immunotherapy drug (Durvalumab)” NCT03623646 ↗ “Durvalumab will be administered as a dose of 1500 mg every 4weeks.” NCT03732274 ↗ “MEDI4736 (durvalumab) by intravenous infusion every two weeks.” NCT02087423 ↗ “Durvalumab 1500 mg will be given on day 1 of each cycle.” NCT05422690 ↗ “MEDI4736 (durvalumab) treatment by intravenous infusion” NCT02352948 ↗ “durvalumab, an anti-PD-L1 monoclonal antibody” PMID 29773326 ↗ May 2018 “Immunotherapy (Durvalumab).” NCT06810609 ↗ “MEDI4736 (Durvalumab)” NCT02678182 ↗ “Durvalumab (Imfinzi)” NCT02423863 ↗ “Drug: Durvalumab” NCT05380713 ↗ “Durvalumab” NCT05742607 ↗ “Durvalumab” NCT06031597 ↗ “durvalumab” NCT03544723 ↗ “Durvalumab” NCT05008861 ↗ “Durvalumab” NCT04954599 ↗ “durvalumab” NCT05429866 ↗ |
| Known as | DUR | “Durvalumab (DUR) is a humanized monoclonal IgG1, anti-PD-L1 antibody with promising data in R/M HNSCC.” PMID 29594250 ↗ Feb 2018 |
| Known as | Durva | “Previously, we showed targeting programmed death-ligand 1 (PD-L1) with durvalumab (durva) and radiation therapy (RT) combination was safe in BC.” PMID 36822667 ↗ Feb 20231“Patients will receive Durva 1120mg, which will be administered by infusion on day 1 of each 21-day cycle.” NCT06954480 ↗ |
| Known as | Durvalumab (Imfimzi) | “Durvalumab (Imfimzi)” NCT04989218 ↗ |
| Known as | Durvalumab (MEDI-4736) | “Durvalumab (MEDI-4736)” NCT03822351 ↗ |
| Known as | durvalumab Injection [Imfinzi] | “durvalumab Injection [Imfinzi]” NCT07174583 ↗ |
| Known as | Imfimzi | “Durvalumab (Imfimzi; MEDI4736; AstraZeneca) is a human monoclonal antibody” NCT04003246 ↗ |
| Known as | Imfinzi | “Durvalumab (Imfinzi) and stereotactic radiotherapy, with each fraction of radiotherapy is given every other day on a standard stereotactic ablative radiotherapy (SAbR) schedule...” NCT04786093 ↗9“This is a phase II, open label single arm, multicentre study of Tremelimumab in combination with Durvalumab (IMFINZI) in preoperative patients with resectable hepatocellular...” NCT05440864 ↗ “Durvalumab 50 MG/1 ML Intravenous Solution [IMFINZI]” NCT06418087 ↗ “Durvalumab (Imfinzi) immunotherapy” NCT05063565 ↗ “Durvalumab Injection [Imfinzi]” NCT04351256 ↗ “Durvalumab (Imfinzi)” NCT02423863 ↗ “Durvalumab (Imfinzi)” NCT03721679 ↗ “Durvalumab (Imfinzi)” NCT03234153 ↗ “Imfinzi” NCT02821754 ↗ |
| Known as | MEDI4736 | “This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab...” NCT05211895 ↗146“This is a multicenter, open-label, dose-escalation, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, pharmacokinetic (PK),...” NCT02671435 ↗ “Phase I Study of Dual Immune Checkpoint Blockade (Anti-PD-L1 (Durvalumab) (MEDI4736) and Anti-CTLA4 (Tremelimumab) Plus Yttrium-90 (Y-90) Radioembolization & Stereotactic Body...” NCT03802747 ↗ “Durvalumab (MEDI4736) 1500mg Q4W in combination with tremelimumab for up to 4 doses/cycles, followed by durvalumab (MEDI4736) 1500mg Q4W for up to a maximum of 8 months with...” NCT03101475 ↗ “Phase II Randomized Study of Neoadjuvant Durvalumab (MEDI4736) Alone Versus Durvalumab (MEDI4736) With Olaparib (AZD2281) in Patients Ineligible for Cisplatin With...” NCT04579133 ↗ “An Investigator Sponsored Phase I Study of the Safety, Tolerability and Pharmacodynamics of Escalating Doses of Combination Treatment of AZD5363 + Olaparib + Durvalumab...” NCT03772561 ↗ “A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicineum (Oportuzumab Monatox, VB4-845) in Subjects With High Grade Non-Muscle-Invasive Bladder...” NCT03258593 ↗ “The CLEAN-DUCT / TRITICC-3 Trial - Phase IIa, Prospective, Single Arm, Open Label, Non-randomized, Multi-center Pilot Study of Durvalumab (MEDI4736) + Intraductal...” NCT06440993 ↗ “A Phase 2 Trial of Durvalumab (MEDI4736) and Tremelimumab With Chemotherapy in Metastatic EGFR Mutant Non-squamous Non-Small Cell Lung Cancer (NSCLC) Following Progression on...” NCT03994393 ↗ “Randomized Phase 2 Study of Preoperative Gemcitabine Plus Cisplatin With or Without Durvalumab (MEDI4736) Followed by Postoperative Durvalumab (MEDI4736) in Patients With...” NCT04308174 ↗ “Durvalumab (initially developed as MEDI4736) is a human monoclonal antibody of the immunoglobulin (Ig) G1 kappa subclass that inhibits binding of PD-L1 (B7-H1, CD274) to PD-1...” NCT04889066 ↗ “Durvalumab (initially developed as MEDI4736) is a human monoclonal antibody of the immunoglobulin (Ig) G1 kappa subclass that inhibits binding of PD-L1 (B7-H1, CD274) to PD-1...” NCT04786093 ↗ “The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly...” NCT02273375 ↗ “A Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab (MEDI 4736) in Patients With Advanced Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, and...” NCT03257761 ↗ “Cohort 1 includes patients on 40mg/ML Gemcitabine/50mg Cisplatin used in combination with 50 mg/mL of intravenous Durvalumab (laboratory code MEDI 4736) every 3 weeks for a...” NCT04617756 ↗ “Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or...” NCT05267392 ↗ “Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and...” NCT06441747 ↗ “A Pilot Neoadjuvant Clinical Trial of Combination Therapy With Abemaciclib, Durvalumab (MEDI4736), and an Aromatase Inhibitor in Locally Advanced Hormone Receptor Positive Breast Cancer” NCT04088032 ↗ “Patients in the durvalumab (MEDI4736) + tremelimumab combination therapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) in combination with tremelimumab (75 mg IV Q4W)” NCT03450967 ↗ “Clinical Study Protocol Drug Substance Durvalumab (MEDI4736) and Tremelimumab Study Code D419CC00002 Version 1.0 Date 09 August 2017 39(219) Pharmacokinetics/pharmacodynamics data.” NCT05440864 ↗ “Phase I/Ib Trial of Radiotherapy in Combination With Durvalumab (MEDI4736) Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma of the Head and Neck (HNSCC)” NCT03635164 ↗ “Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.” NCT07027436 ↗ “A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA).” PMID 32591370 ↗ Jun 2020 “Phase II Trial of Durvalumab (MEDI4736 )/Tremelimumab Combined With Definitive Concurrent Chemo-radiotherapy for Inoperable Esophageal Squamous Cell Carcinoma” NCT03377400 ↗ “Durvalumab (MEDI4736) will be supplied in glass vials containing 500 mg of liquid solution at a concentration of 50 mg/mL for intravenous(IV) administration.” NCT04293419 ↗ “Durvalumab (MEDI4736) Combined With Anlotinib Versus Durvalumab (MEDI4736) Alone as Maintenance Therapy in Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)” NCT04985851 ↗ “An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Patients With Extensive Stage Small-Cell Lung Cancer” NCT05245994 ↗ “Assessing the Immunomodulatory Effects of Pharmacologic Ascorbate With Durvalumab (MEDI 4736) in Non-Small Cell Lung Cancer: A Window of Opportunity Trial” NCT06083454 ↗ “A Phase II Study of Durvalumab (MEDI 4736) Maintenance in Frail Limited Disease Small Cell Lung Cancer Patients After Thoracic Chemoradiotherapy (CRT)” NCT05617963 ↗ “Patients in the durvalumab (MEDI4736) monotherapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) once prior to surgery in this study.” NCT03737968 ↗ “A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer” NCT04499053 ↗ “Trabectedin Combined With Durvalumab (MEDI4736) in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas. A Phase Ib Study.” NCT03085225 ↗ “Durvalumab (MEDI4736) Plus Tremelimumab in Resectable, Locally Advanced Squamous Cell Carcinoma of the Oral Cavity: a Window of Opportunity Study” NCT03784066 ↗ “Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome Sequencing” NCT03608865 ↗ “A Phase 1b Pharmacodynamic Study of Durvalumab (MEDI4736) in Patients With HER-2 Positive Metastatic Breast Cancer (MBC) Receiving Trastuzumab” NCT02649686 ↗ “A Phase II Study of Durvalumab (MEDI 4736) for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection” NCT04294498 ↗ “A Randomized Double Blind Phase II Trial of Restorative Microbiota Therapy (RMT) in Combination With Durvalumab (MEDI4736) and Chemotherapy” NCT04105270 ↗ “A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)” NCT02318277 ↗ “A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)” NCT03899610 ↗ “Phase 2 Investigation of MEDI4736 (Durvalumab) and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors” NCT03911557 ↗ “Durvalumab (MEDI4736) is a human monoclonal antibody directed against PD-L1 in development for the treatment of many cancers.” NCT03959293 ↗ “Neoadjuvant Anti-PD-L1 (Durvalumab/MEDI4736) Plus Anti-CTLA-4 (Tremelimumab) and Radiation for High Risk Soft-Tissue Sarcoma” NCT03116529 ↗ “Imaging Tumor-infiltrating CD8+ T-cells in Non-small Cell Lung Cancer Upon Neo-adjuvant Treatment With Durvalumab (MEDI4736)” NCT03853187 ↗ “Phase I/II of Durvalumab (MEDI4736) + Tremelimumab + Stereotactic Body Radiotherapy for Metastatic Head and Neck Carcinoma” NCT03283605 ↗ “Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations” NCT05659914 ↗ “durvalumab (MEDI4736) 20mg/kg via IV infusion every 4 weeks until confirmed disease progression or unacceptable toxicity” NCT02978482 ↗ “Intensified Chemo-immuno-radiotherapy With Durvalumab (MEDI4736) for Stage III Non-Small Cell Lung Cancers (NSCLCs)” NCT04230408 ↗ “durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201)” NCT05221840 ↗ “Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)” NCT05215106 ↗ “A phase 1 study examining the combination of Durvalumab (MEDI4736) and Trabectedin in various solid tumor types.” NCT03496519 ↗ “The immunotherapy candidate of this study is durvalumab (MEDI4736) targeting PD-L1 (programmed death-ligand 1).” NCT05116254 ↗ “Using Low-dose Radiotherapy (LDRT) Combined With Durvalumab (MEDI4736), Etoposide, and Cisplatin/Carboplatin” NCT05092412 ↗ “Durvalumab (MEDI4736), a PD-L1 Antibody for Sarcomas Including Malignant Peripheral Nerve Sheath Tumors” NCT05253131 ↗ “Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients With Recurrent Ovarian Cancer” NCT04742075 ↗ “Durvalumab (MEDI4736, 10 mg/kg every 2 weeks) was administered intravenously for up to 12 months.” PMID 27269937 ↗ Jun 2016 “Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects” NCT04361825 ↗ “Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study” NCT04392505 ↗ “durvalumab (MEDI4736) , which is an antibody drug that help un-block parts of the immune system” NCT02764333 ↗ “consolidation Durvalumab (MEDI4736) in resectable and borderline resectable Stage IIIA/B NSCLC” NCT06810609 ↗ “Durvalumab (MEDI4736), at 1500 mg fixed dose, administered intravenously (IV) over 60 minutes.” NCT03912818 ↗ “Study Evaluating Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738)” PMID 40781023 ↗ Jul 2025 “Durvalumab (MEDI4736) is an anti-PD-L1 monoclonal antibody immunotherapy for lung cancer.” NCT03818776 ↗ “Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma” NCT06446570 ↗ “AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer” NCT04525391 ↗ “Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)” NCT03472274 ↗ “A Study of Durvalumab (MEDI4736), as an Adjuvant Therapy, Compared to Observation Alone” NCT03038477 ↗ “CKD-516 Tablet Combined With Durvalumab(MEDI4736) in Patient Refractory Solid Tumors” NCT04696848 ↗ “Durvalumab (MEDI4736) is a human monoclonal antibody that inhibits binding of PD-L1.” NCT03802071 ↗ “Antibody Durvalumab (MEDI4736) in Combination With Olaparib and/or Cediranib” NCT02484404 ↗ “Durvalumab (Imfimzi; MEDI4736; AstraZeneca) is a human monoclonal antibody” NCT04003246 ↗ “adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy” NCT04159974 ↗ “neoadjuvant durvalumab (MEDI 4736) and platinum-based Chemotherapy” NCT06998719 ↗ “durvalumab (MEDI4736) in combination with oleclumab (MEDI9447)” NCT06606847 ↗ “Durvalumab (MEDI4736) Plus OLAparib Plus Fulvestrant” NCT04053322 ↗ “Durvalumab (MEDI4736) With or Without Tremelimumab” NCT02788773 ↗ “Neoadjuvant Durvalumab (MEDI4736) Plus Docetaxel” NCT04221555 ↗ “Investigational Product: Durvalumab (MEDI4736)” NCT05262985 ↗ “Anti-PD-L1 Inhibitor Durvalumab (MEDI4736)” NCT03419559 ↗ “Durvalumab [MEDI4736](Anti-PD-L1 Antibody)” NCT03015129 ↗ “Anti-PD-L1 Antibody, Durvalumab (MEDI4736)” NCT02737072 ↗ “Durvalumab, MEDI4736, is a immunotherapy,” NCT03795207 ↗ “Durvalumab (MEDI 4736) 1.12g IV q3w” NCT04015739 ↗ “Durvalumab (Anti-PDL1) (MEDI4736)” NCT03982173 ↗ “Durvalumab (MEDI4736) (Anti-PDL1)” NCT03430518 ↗ “MEDI4736 (Durvalumab) monotherapy” NCT02516241 ↗ “Anti-PD-L1 Durvalumab (MEDI4736)” NCT03249142 ↗ “Drug: Durvalumab; MEDI4736” NCT02793466 ↗ “Durvalumab (MEDI 4736)” NCT03148327 ↗ “Durvalumab (MEDI4736)” NCT03528694 ↗ “MEDI4736 (Durvalumab)” NCT02453282 ↗ “Durvalumab (Medi4736)” NCT03215095 ↗ “Durvalumab (MEDI4736)” NCT03665129 ↗ “MEDI4736 (Durvalumab)” NCT03084471 ↗ “Durvalumab (MEDI4736)” NCT04699838 ↗ “Durvalumab [MEDI4736]” NCT03212469 ↗ “Durvalumab (MEDI4736)” NCT03833440 ↗ “Durvalumab (MEDI4736)” NCT04522544 ↗ “MEDI4736 (durvalumab)” NCT02205333 ↗ “Durvalumab (MEDI4736)” NCT05856695 ↗ “Durvalumab (MEDI4736)” NCT03003962 ↗ “Durvalumab (MEDI4736)” NCT03430895 ↗ “Durvalumab (MEDI4736)” NCT04223648 ↗ “durvalumab (MEDI4736)” NCT07012798 ↗ “IMT-B; MEDI4736” NCT02179671 ↗ “MEDI4736” NCT03618134 ↗ |
| Known as | MEDI4736 (durvalumab) | “MEDI4736 (durvalumab)” NCT02588131 ↗1“MEDI4736 (Durvalumab)” NCT03775486 ↗ |
| Known as | MedImmune 4736 | “MEDI4736 (MedImmune 4736) monotherapy” NCT02527434 ↗ |
| Action | Inhibit | “durvalumab (anti-PD-L1)” PMID 33288749 ↗ Dec 2020 |
| Modality | Monoclonal antibody | “MEDI4736 (a monoclonal antibody that targets programmed cell death ligand-1 (PD-L1))” NCT01693562 ↗ |
| Route | Intravenous | “Durvalumab, 1120 mg Q3W, IV for 12 weeks” NCT01042379 ↗ |
| Target | CD274 | “MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb).” NCT02000947 ↗ |